Trevi Therapeutics Files 8-K on Director and Officer Changes
Ticker: TRVI · Form: 8-K · Filed: Oct 1, 2024 · CIK: 1563880
Sentiment: neutral
Topics: corporate-governance, executive-compensation, board-of-directors
TL;DR
Trevi Therapeutics updated its board and exec pay structure on 9/27.
AI Summary
On September 27, 2024, Trevi Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing includes the election of new directors and updates to compensatory plans for its officers, reflecting ongoing corporate governance adjustments.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing primarily concerns corporate governance and executive compensation, which typically carries a lower immediate risk compared to financial distress or major operational changes.
Key Players & Entities
- Trevi Therapeutics, Inc. (company) — Registrant
- September 27, 2024 (date) — Date of earliest event reported
FAQ
What specific changes were made to the board of directors?
The filing indicates the election of directors and potential changes in officer appointments, but the specific names and details of the new directors are not provided in the excerpt.
What is the nature of the compensatory arrangements being updated?
The filing mentions updates to 'Compensatory Arrangements of Certain Officers,' suggesting changes to executive pay or incentive plans, though specific details are not elaborated in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on September 27, 2024.
What is Trevi Therapeutics, Inc.'s principal executive office address?
Trevi Therapeutics, Inc.'s principal executive offices are located at 195 Church Street, 16th Floor, New Haven, Connecticut 06510.
What is the Commission File Number for Trevi Therapeutics, Inc.?
The Commission File Number for Trevi Therapeutics, Inc. is 001-38886.
Filing Stats: 667 words · 3 min read · ~2 pages · Grade level 11.2 · Accepted 2024-09-30 17:37:53
Key Financial Figures
- $0.001 — e on which registered Common stock, $0.001 par value per share TRVI The Nasdaq
- $400 — Dr. Clark consulting fees at a rate of $400 per hour. A copy of the Company's pre
Filing Documents
- trvi-20240927.htm (8-K) — 49KB
- trvi-ex99_1.htm (EX-99.1) — 19KB
- img251553556_0.jpg (GRAPHIC) — 26KB
- 0000950170-24-110462.txt ( ) — 229KB
- trvi-20240927.xsd (EX-101.SCH) — 28KB
- trvi-20240927_htm.xml (XML) — 5KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press release dated September 30, 2024* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * The information contained in this Exhibit 99.1 attached hereto relating to Item 5.02 shall be deemed to be furnished, and not filed.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TREVI THERAPEUTICS, INC. Date: September 30, 2024 By: /s/ Lisa Delfini Name: Lisa Delfini Title: Chief Financial Officer